Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MRT4 homolog, ribosome maturation factor (MRTO4) is a nuclear protein involved in the early stages of assembly and maturation of the large (60S) ribosomal subunit[4][5][7]. It is a paralog of ribosomal protein P0, dynamically shuttling between the nucleus and cytoplasm during ribosome biogenesis, but cannot substitute for P0 in mature ribosomes[2][4][7]. MRTO4 localizes primarily in the nucleolus and undergoes regulatory phosphorylation that modulates its molecular behavior under stress[2]. Elevated MRTO4 expression has functional consequences in cancer biology, notably promoting glycolysis and hepatocellular carcinoma progression by inhibiting the metabolic enzyme ALDOB, and is associated with enhanced proliferation, invasion, and resistance to apoptosis in tumor cells[2][3]. While direct targeting by approved drugs is not established, MRTO4 serves as an independent prognostic marker and potential therapeutic target in cancer[3].
Not applicable (no drugs directly targeting MRTO4 listed) In cancer, inhibition of MRTO4 could suppress glycolysis, cell proliferation, and invasion
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MRT4 homolog, ribosome maturation factor (MRTO4).